743P Combined analysis of overall survival (OS) from the phase III CodeBreaK 300 and phase Ib CodeBreaK 101 studies of sotorasib 960 mg plus panitumumab (soto960+pani) therapy for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC).
Saved in:
| Title: | 743P Combined analysis of overall survival (OS) from the phase III CodeBreaK 300 and phase Ib CodeBreaK 101 studies of sotorasib 960 mg plus panitumumab (soto960+pani) therapy for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC). |
|---|---|
| Authors: | Kuboki, Y.1 (AUTHOR), Pietrantonio, F.2 (AUTHOR), Salvatore, L.3 (AUTHOR), Meriggi, F.A.4 (AUTHOR), Modest, D.P.5 (AUTHOR), Yaeger, R.6 (AUTHOR), Ruiz, E.7 (AUTHOR), Taieb, J.8 (AUTHOR), Karamouzis, M.V.9 (AUTHOR), Esaki, T.10 (AUTHOR), Kim, T.W.11 (AUTHOR), Cremolini, C.12 (AUTHOR), Strickler, J.H.13 (AUTHOR), Masuishi, T.14 (AUTHOR), Paez, D.15 (AUTHOR), Chan, E.16 (AUTHOR), Chao, J.16 (AUTHOR), Tran, Q.17 (AUTHOR), Fakih, M.18 (AUTHOR), Hong, D.S.19 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS518-S519. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2025.08.1317 |
